Front Page News
Summit of Strength Program Receives Positive Feedback and Increases Attendance
Attendance and feedback have been extremely positive for this new program. The Cure SMA Summit of Strength Program kicked off in July and has continued […]
Registration is Now Open for the 2019 Annual SMA Conference!
Registration is now open for the 2019 Annual SMA Conference! This year’s conference will be held at the Disneyland Hotel in Anaheim, CA from Friday, […]
Kansas Adopts SMA Newborn Screening as Several Other States Move Closer to Adoption
Progress is currently being made in several states for getting SMA added to Newborn Screening panels. We are delighted to share this news with you […]
Meet the NDEAM Webinar Panelists
October is National Disability Employment Awareness Month (NDEAM)! Hear directly from adults living with SMA in the workforce. Register for Cure SMA’s first NDEAM webinar. […]
Meet the National Disability Employment Awareness Month (NDEAM) Panelists
October is National Disability Employment Awareness Month (NDEAM)! Hear directly from adults living with SMA in the workforce. Register for Cure SMA’s first NDEAM webinar. […]
NDEAM Spotlight: Jaclyn Greenwood
The below guest blog post was written by Jaclyn Greenwood in honor of National Disability Employment Awareness Month. Jaclyn is a board certified genetic counselor […]
National Disability Employment Awareness Month Spotlight: Kim Hill
The below NDEAM Spotlight was written by Kim Hill, Disability Integration Specialist at the Oklahoma Department of Emergency Management, who also lives with SMA Type […]
Register for Cure SMA’s First National Disability Employment Awareness Month Webinar
October is National Disability Employment Awareness Month (NDEAM)! In its honor, Cure SMA is hosting our first NDEAM webinar where the audience will hear directly […]
AveXis Issues Community Statement on FDA Filing for SMA Type I
AveXis has provided the following community statement on their FDA filing for SMA type I. Dear SMA Community, AveXis, a Novartis company, is pleased to […]
AveXis Files for FDA Approval of Gene Therapy for Spinal Muscular Atrophy
Type I
AveXis, Inc., a Novartis company, today announced that they have filed for FDA approval of AVXS-101, a gene therapy that replaces the survival motor neuron […]